Next 10 |
2020 represented a year full of turmoil and despair for some and opportunity for others. There were 154 deals worth over $605 billion announced in 2020. The most interesting aspect of the year was how wide the spreads were in March 2020. For further details see: U.S. Mer...
Merger activity increased last week with four new deals announced and seven deals closing. Over the past month, we have seen early signs of a pickup in new deals and two large deals announced in the energy and healthcare sectors. The acquisition of Noble Energy by Chevron was a significant d...
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
Merger activity remained steady last week with three new deals announced and two deals closing. There has not been any significant M&A activity this year in the energy sector with oil prices collapsing due to the COVID-19 pandemic. After choosing to walk away from a bidding war with Oc...
Merger activity increased last week with three new deals announced and one deal closing. The biggest highlight for last week was the acquisition of Maxim Integrated Products (MXIM) by Analog Devices (ADI) in an all-stock deal for $21 billion, which is the largest deal so far this year. The...
Merger activity remained steady last week with one new deal announced, six deals closing and one deal called off. The month of June ended with six active deals being completed and another deal terminated, resulting in a total of five deals terminated in a single month. June was also the most...
Merger activity decreased last week with one new deal announced, two deals closing, and one deal called off. After terminating deals with AcelRx Pharmaceuticals (ACRX) and Melinta Therapeutics (MLNT), Tetraphase Pharmaceuticals (TTPH) agreed to be acquired by La Jolla Pharmaceutical Company ...
La Jolla Pharmaceutical (NASDAQ: LJPC ) and Tetraphase Pharmaceuticals (NASDAQ: TTPH ) have entered into a definitive merger agreement, under which La Jolla would acquire Tetraphase, through a tender offer, for $43M in upfront cash plus potential future cash payments of up to $16M pursuant...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Tetraphase Pharmaceuticals Inc. Company Name:
TTPH Stock Symbol:
NASDAQ Market:
Tetraphase Pharmaceuticals Inc. Website:
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an uns...